Tillomed Laboratories ltd

Information

Name

Type

Company

Roles

Supplier

Company Size

Large

Company Number

Incorporation Date

Website

Address

LUTON

United Kingdom

Suppliers

Unlock the full supplier list, free!

Sign up to unlock the full list of suppliers associated with Tillomed Laboratories ltd
Sign up free

Contracts awarded to Tillomed Laboratories ltd

The contracts that Tillomed Laboratories ltd have been awarded to supply. Click on the contract to view more detailed information and view the full details about the contract won.

Award

Published 1 month ago

NP39724 Generic and Biosimilar Cancer Medicines

Supply of Generic and Biosimilar Cancer Medicines to NHS Scotland.

£10,396,962
Award

Published 3 months ago

NHS National Generic Pharmaceuticals Wave 15a

NHS National Generic Pharmaceuticals - Wave 15a. Offer reference number: CM/PHG/23/5697. Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: CM/PHG/23/5697/01 – Orals (plus non-parenteral) Products: All Regions (CESW/LSNE/NWLN): 01/02/2025 to 31/05/2027 (28 Months) CM/PHG/23/5697/02 – Hospital Only Products: DNW & DLN: 01/02/2025 to 31/01/2027 (24 months) CM/PHG/23/5697/03 – Hospital Only Products (Housekeeping): DLS & DNE: 01/02/2025 to 31/05/2026 (16 months) DCE & DSW: 01/02/2025 to 30/09/2025 (8 months)

£170
Award

Published 5 months ago

NHS National Framework for Transition products commencing 1 October 2024

Project title: NHS National Framework for Transition products commencing 1 October 2024 Offer reference number: CM/TNS/24/5712 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months. Potential periods of call-offs under the framework agreement: CM/TNS/24/5712/01 - Amphotericin liposomal Injection, bexarotene capsules, dabigatran capsules, plerixafor injection and rivaroxaban tablets Lot 1 CESW: 01/10/2024 to 30/09/2025 (12 months) Lot 2 NWLN: 01/10/2024 to 30/09/2025 (12 months) Lot 3 LSNE: 01/10/2024 to 31/05/2026 (20 months) CM/TNS/24/5712/02 - Imatinib Lot 1 DSW: 01/10/2024 to 30/09/2025 (12 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

£41,320,000 Bids close: 8 months ago
Award

Published 5 months ago

NHS National Framework for Transition products commencing 1 October 2024

Project title: NHS National Framework for Transition products commencing 1 October 2024 Offer reference number: CM/TNS/24/5712 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months. Potential periods of call-offs under the framework agreement: CM/TNS/24/5712/01 - Amphotericin liposomal Injection, bexarotene capsules, dabigatran capsules, plerixafor injection and rivaroxaban tablets Lot 1 CESW: 01/10/2024 to 30/09/2025 (12 months) Lot 2 NWLN: 01/10/2024 to 30/09/2025 (12 months) Lot 3 LSNE: 01/10/2024 to 31/05/2026 (20 months) CM/TNS/24/5712/02 - Imatinib Lot 1 DSW: 01/10/2024 to 30/09/2025 (12 months) Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England

£13
Award

Published 7 months ago

Generic, Branded Generic & Proprietary Medicinal Products - Group 14

Generic, Branded Generic & Proprietary Medicinal Products - Group 14 (5190931)

£10,725,841
Award

Published 10 months ago

NHS National Generic Pharmaceuticals Wave 14c (CF Award - Part 2)

Invitation to offer for NHS National Generic Pharmaceuticals - Wave 14c Offer reference number: CM/PHG/22/5672 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 36 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: Orals (plus non-parenteral) Products: All Regions (CESW/LSNE/NWLN):01/06/2024 to 31/05/2027 (36 Months) Hospital Only Products: DLS & DNE: 01/06/2024 to 31/05/2026(24 months) Hospital Only Products(Housekeeping): DLN & DNW: 01/06/2024 to 31/01/2025(8 months) DCE & DSW: 01/06/2024 to 30/09/2025(16 months)

£424,035,364 Bids close: 1 year ago

Contacts

+44 7903184225

Statistics (1 Year)

Contracts Won

Total Won

£50,770,071

Average Win

£16,923,357

Tillomed Laboratories ltd

Information

Name

Type

Roles

Company Size

Company Number

Incorporation Date

Website

Address

Suppliers

Contracts awarded to Tillomed Laboratories ltd

NP39724 Generic and Biosimilar Cancer Medicines

NHS National Generic Pharmaceuticals Wave 15a

NHS National Framework for Transition products commencing 1 October 2024

NHS National Framework for Transition products commencing 1 October 2024

Generic, Branded Generic & Proprietary Medicinal Products - Group 14

NHS National Generic Pharmaceuticals Wave 14c (CF Award - Part 2)

Contacts

Statistics (1 Year)

Contracts Won

Total Won

Average Win